Market Signal Briefing

Ethereum price started a recovery wave above $4,050. ETH is now consolidating and might aim for more gains if it clears the $4,170 resistance.

Ethereum remained stable above $3,820 and started a recovery wave.
The price is trading above $4,050 and the 100-hourly Simple Moving Average.
There was a break above a key bearish trend line with resistance at $4,000 on the hourly chart of ETH/USD (data feed via Kraken).
The pair could continue to move up if it settles above $4,170 and $4,200.

Ethereum Price Recovers
Ethereum price remained supported above the $3,820 level and started a recovery wave, like Bitcoin. ETH price was able to recover above the $3,880 and $4,000 resistance levels.

There was a clear move above the 50% Fib retracement level of the downward wave from the $4,275 swing high to the $3,826 low. Besides, there was a break above a key bearish trend line with resistance at $4,000 on the hourly chart of ETH/USD.

Ethereum price is now trading above $4,050 and the 100-hourly Simple Moving Average. On the upside, the price could face resistance near the $4,150 level. The next key resistance is near the $4,170 level or the 76.4% Fib retracement level of the downward wave from the $4,275 swing high to the $3,826 low.

Source: ETHUSD on TradingView.com
The first major resistance is near the $4,200 level. A clear move above the $4,200 resistance might send the price toward the $4,250 resistance. An upside break above the $4,250 region might call for more gains in the coming sessions. In the stated case, Ether could rise toward the $4,320 resistance zone or even $4,350 in the near term.

Another Decline In ETH?
If Ethereum fails to clear the $4,200 resistance, it could start a fresh decline. Initial support on the downside is near the $4,050 level. The first major support sits near the $4,000 zone.

A clear move below the $4,000 support might push the price toward the $3,920 support. Any more losses might send the price toward the $3,880 region in the near term. The next key support sits at $3,820.

Technical Indicators

Hourly MACD – The MACD for ETH/USD is losing momentum in the bullish zone.

Hourly RSI – The RSI for ETH/USD is now above the 50 zone.

Major Support Level – $4,050

Major Resistance Level – $4,200

CoinGecko poll reveals sharp divide as newcomers wary over Bitcoin's mainstream embrace.

A new CoinGecko survey revealed a cautious divide in the community over Bitcoin’s growing mainstream acceptance, as newcomers show the most skepticism. The poll, which was conducted between August 22 and September 11, 2025, gathered responses from 2,549 participants.

It found that while a majority lean positive, a significant minority remains wary of how Wall Street and traditional finance may reshape the asset.

Wall Street vs. Decentralization
Overall, 60% of respondents said mainstream adoption, including developments such as spot ETFs, corporate treasuries holding Bitcoin, and government accumulation, is positive for Bitcoin. Within this group, 41.4% described the trend as “very positive,” and cited greater legitimacy and long-term price potential, while 18.6% felt “positive” but expressed less enthusiasm.

Another 19.4% of participants were neutral. However, 20.5% voiced concerns that Bitcoin’s expansion into traditional finance could compromise its core principles. This group included 12.7% who see mainstream adoption as “very negative.” They warned that decentralization and censorship resistance may be weakened. Meanwhile, 7.8% were “negative” but less strongly opposed.

The skepticism was most pronounced among first-cycle investors, who experienced their first crypto market cycle. Among these newcomers, 29.3% viewed mainstream adoption as negative or very harmful, roughly double the 14.9% rate recorded among second-cycle participants and 15.7% among those in their third cycle or beyond.

On the other hand, only 52.0% of first-cycle participants felt positive or very positive about Bitcoin’s mainstream momentum, compared with 65.2% of second-cycle respondents and 64.4% of long-term veterans. Second-cycle participants were also the most likely to call mainstream adoption “very positive.”

The findings suggest that seasoned crypto users are more comfortable with the idea of institutional involvement, while newer entrants may either lack exposure to past adoption cycles or represent speculative traders wary of Bitcoin becoming another Wall Street asset.

You may also like:

Analysts Predict Massive ‘Uptober’ Rally Despite This Week’s Market Rout

Ethereum Joins $1.9B Crypto Surge, Bitcoin Bags $977M as Investors Pile Back In

Bitcoin Taps 4 Week High of $117K Ahead of Fed Rate Decision

Crypto Demographics
Among the participants, CoinGecko found that 68% identified as long-term crypto investors, while 20% described themselves as short-term traders. Builders made up 7% of the group, and 5% were sidelined spectators observing the market without active participation.

In terms of experience, 38% were navigating their first market cycle with up to three years in crypto, 41% were in their second cycle spanning four to seven years, and 21% were seasoned veterans with over eight years of involvement.

Geographically, respondents were concentrated in Europe, which accounted for 31% of participants, followed by Asia at 26% and North America at 22%. The remaining participants were spread across Africa, South America, and Oceania.

Tags:

The Pi Network hackathon, launched on August 21, 2025, has reached its midpoint check-in on September 19. The Core Team released a dedicated update video showcasing projects from the community. Final submissions are due by October 15, 2025.

Hackathon Innovations
The showcased apps highlight real-world Pi use cases:

Starmax: lets users buy goods with Pi.

Nature’s Pulse: connects consumers with farmers to deliver fresh produce directly.

Eternal Rush: a Pi-native online game.

ReloadPi: enables token holders to purchase from 300+ brands, including pizza and beverages.

StreamPi: a content-sharing app where uploads cost just one Pi token.

The hackathon includes a 160,000 Pi prize pool, split as follows:

1st place – 75,000 Pi

2nd place – 45,000 Pi

3rd place – 15,000 Pi

Honorable mentions (up to 5 teams) – 5,000 Pi each

Despite event success, Pi (PI) is facing steep declines. On Sept 22, 2025, PI hit a new all-time low of just over $0.25, currently trading only 2.3% above that level. The token is down 25% weekly and has dropped 7.64% over the past 60 days.

Adding pressure, 13.4 million PI tokens are set to unlock on October 1 and October 4, 2025, raising fears of further sell-offs.

Outlook for Pioneers
The hackathon demonstrates Pi Network’s effort to drive utility and adoption within its ecosystem, even as its token price struggles. Analysts suggest the upcoming October token unlocks will be a critical moment for both developers and investors watching PI’s long-term trajectory.

Disclaimer: This is a sponsored press release. CryptosNewss does not endorse or guarantee the content. Readers should verify facts and conduct independent research before making financial decisions.

Bhavesh

Bhavesh is a dedicated content writer with a keen eye for detail and a passion for blockchain and cryptocurrency. His interest in these fields was sparked through his work, and he continues to expand his knowledge in these areas. He loves to watch anime and binge watches during his free time.

The pizza company reports earnings in a few weeks.

Domino's Pizza (DPZ 3.14%) is an iconic pizza chain with a presence in dozens of countries throughout the world. And in the U.S. alone, it has more than 7,000 locations. It's an attractive go-to fast food option for people looking for a quick and easy meal. It is a well-known brand and it has even attracted the interest of billionaire investor Warren Buffett. His company, Berkshire Hathaway, invested in the pizza maker last year.

Over the past five years, however, Domino's has been an underwhelming investment to own, rising by around 1% during that stretch (returns as of Sept. 25). Could it be due for a much bigger rally, and could its third-quarter earnings report, which comes out on Oct. 14, be the catalyst that sends the stock higher? Let's take a closer look at the stock and how it has performed in the past.

Image source: Getty Images.

How Domino's has performed after previous earnings reports
The last time that Domino's reported earnings was back in July. At the time, the company posted solid numbers as its same-store sales in the U.S. came in at 3.4%, which was better than analyst estimates of 2%. Unfortunately, its bottom line was less than stellar, with its diluted earnings per share coming in at $3.81, which was lower than what Wall Street was looking for -- $3.95.But despite the fairly decent showing, Domino's stock would proceed to fall shortly after the earnings numbers came out.

DPZ data by YCharts

In the past three earnings reports, Domino's stock has ended up falling in value afterward. And from the chart above, it's clear that while there have been some positive increases in the share price following the release of earnings, oftentimes there's been a decline. After all, Domino's isn't in a high-growth sector like technology and so the likelihood of it generating a lot of excitement on its earnings numbers is unlikely.

The more pressing concerns may be about what lies ahead for the business. And with tariffs and considerable macroeconomic uncertainty, investors may not be overly optimistic. It also doesn't help that Domino's isn't a cheap stock.

Domino's trades at a high multiple given its growth
Although Domino's hasn't been doing badly, the stock is trading at a not-so-modest valuation. Currently, its price-to-earnings (P/E) multiple sits at around 25. That's in line with the S&P 500 average, but it's still a bit pricey for a business that's growing in the single digits. This is not the type of growth chart I would expect to see from a stock that trades at 25 times its earnings.

DPZ Revenue (Quarterly YoY Growth) data by YCharts

With modest growth at a time when consumers may be cutting back on discretionary spending and perhaps eating at home more often, my concern is that the company's already-underwhelming growth rate may come down even further in future quarters. Even though Domino's may have a strong and profitable business, its valuation may be what's hurting the stock from rising a whole lot higher right now.

I wouldn't rush to buy Domino's stock
A positive earnings report can often boost a stock's value in both the short and long term, but unless Domino's has a completely unexpected blowout quarter, I wouldn't expect that to happen when it reports earnings in a few weeks. At best, I can see the stock rising a few percentage points if it continues to show good same-store comps. But at worst, I could see a sizable decline given its valuation. There looks to be more downside risk than there is upside potential based on where it trades today.

The stock has been flat this year and there's little reason to expect that to change after it posts its upcoming earnings. There is no rush to buy, and waiting until after the company reports its latest numbers before making a decision on the stock may be a sound option for investors.

David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Berkshire Hathaway and Domino's Pizza. The Motley Fool has a disclosure policy.

LOS ANGELES, Sept. 28, 2025 (GLOBE NEWSWIRE) -- Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”), a California-based global shared intelligent electric mobility ecosystem company, today shared a weekly business update from YT Jia, Founder and Global Co-CEO of FF.

A mere handful of months ago, Tesla ((TSLA - Free Report) ) shares looked doomed, and it felt as if the bears may have finally gotten their long-awaited moment. Tesla CEO Elon Musk made his foray into politics by spending more than a quarter of a billion dollars to support Donald Trump and the Republicans in 2024. Then, while already spread thin, he took a hiatus from Tesla and managed the ‘Department of Government Efficiency’ DOGE to help seek a solution to America’s soaring debt.

However, Musk would soon learn the reality of getting involved in politics in today’s toxic environment. Many democrats felt that Musk wielded too much power, leading to mass left-wing protests against Tesla, boycotts, and widespread vandalism. As if that weren’t bad enough, Musk had a ugly falling out with President Trump, leading to backlash from many partisans on the right. Meanwhile, Tesla’s legacy EV business was slowing, Alphabet’s ((GOOGL - Free Report) ) ‘Waymo’ seemed poised to dominate the robotaxi market, and even some of Musk’s staunchest followers began to lose faith in him, voicing concerns that he was no longer interested in running Tesla.

Tesla is on Pace for its Best September Performance EverHowever, if there’s one lesson Tesla has taught investors, it’s never to make a long-term bet against Elon Musk and Tesla, no matter how bad things may seem. Despite the slew of bearish headlines and negative earnings growth, TSLA is about to register its best September in history. Tesla shares up more than 30% in September and registered fresh all-time closing highs last week.

Image Source: Zacks Investment Research

Why are Tesla Shares Rising? Tesla shares are rising for several reasons. The September rally was sparked when Elon Musk confirmed that he was done with politics. For investors, the news was a massive sigh of relief. The importance of Musk’s presence at Tesla was put on full display when he stepped away from Tesla to focus on his acquisition of social media platform Twitter, and TSLA shares dropped swiftly. In addition to Musk leaving politics, investors also cheered the Tesla board’s $1 trillion pay package proposal for Musk, seeing the offer as a way to keep Musk at Tesla and motivated.

Tesla shareholders are once again betting on the future. Tesla’s robotaxi service is finally live in Austin and San Francisco, with plans to expand into other cities like Miami and Chicago (pending regulatory approval). In addition, TSLA shares are rising on optimism surrounding its newest ‘Full Self Driving’ (FSD) update, which is slated to launch this week. Tesla FSD v14 will be launched to a limited number of social media influencers this week, with v14.2 set to follow in a few weeks. In a recent tweet, Musk hyped the debut, saying that “The car will feel like it is sentient being by 14.2.”

Tesla Q3 Delivery & Production Preview Though Tesla is working to diversify its business with its energy segment and its upcoming ‘Optimus” humanoid robot, Tesla currently generates roughly three-quarters of its total revenue from its legacy EV business. Unfortunately for Tesla bulls, deliveries are 4% lower over the trailing twelve months, and over the past two years, growth has been sluggish at +1%. Tesla deliveries peaked in Q4 2023 and have been declining ever since.

Image Source: Zacks Investment Research

However, Tesla has a chance to change the narrative this week when it releases its third-quarter delivery and production numbers, which are expected to drop on Thursday before the US equity market opens. Below is a breakdown of Wall Street’s expectations for Tesla’s Q3 delivery numbers:

·       Q3 Delivery Expectations: Consensus Wall Street analyst expectations are for 448,000 units. (According to FactSet)

·       Delivery Comparison to 2024: Tesla delivered 462,890 vehicles in Q3 2024.

·       Q3 Production Expectations: UBS expects 470k vehicles produced in Q3 2025.

·       2025 Full-Year Delivery Outlook: Tesla delivered 336,681 vehicles in Q1 and 384,122 cars in Q2. Wall Street consensus estimates anticipate ~1.85 million vehicles will be delivered in full-year 2025.

The Q3 delivery and production numbers will be significantly different from those of previous quarters for several reasons, including tariff impacts, the expiration of the EV tax credit, and the release of the new Model Y.

Why Tesla Will Beat Q3 Wall Street Delivery ExpectationsThough there are several crosscurrents heading into Thursday’s delivery number, there are several reasons for Tesla bulls to be optimistic, including:

1.       Tax Credit Expiration-Related Demand: Elon Musk has stated that he supports ending the $7,500 US federal EV tax credit, arguing that it would benefit Tesla and negatively impact its competitors. However, Musk later retracted his statement, arguing that it is unfair that President Trump’s ‘Big Beautiful Bill’ leaves oil and gas subsidies while sunsetting EV and solar incentives. Nevertheless, regardless of what Musk says, Q3 Tesla deliveries are likely to benefit dramatically from a ‘pull forward’ effect, as consumers likely have rushed over the past few months to take advantage of the $7,500 EV tax credit that won’t be available for the first time since the program started in 2009.

2.       Elon Musk’s Political Backlash Has Dissipated: While Tesla sales have undoubtedly suffered from Elon Musk’s political affiliations and controversial statements, his stepping back from politics and renewed focus on Tesla should help to alleviate these concerns. Although there are critics on both sides of the political aisle who will never buy a Tesla out of principle, Tesla remains the safest, most popular, and highest-quality EV on the market by far. In addition, Wall Street analysts are likely underestimating the loyalty of Tesla’s customer base. Tesla, which is famous for spending little to no money on marketing, may even benefit from loyalists buying Teslas simply to support Musk. Additionally, Elon Musk was recently seen shaking hands with President Trump at the Charlie Kirk memorial service, an act that may help repair his reputation in right wing political circles. In summary, time heals wounds, especially in the hyperactive modern-day news cycle of 2025.

3.       The Model Y Retool is Complete: Tesla’s Model Y SUV has been a smash hit. Since 2023, the Model Y has been the top-selling electric vehicle by far. Tesla recently begun selling a revamped and sleeker ‘Juniper’ Model Y, featuring exterior and interior aesthetic updates, new lighting, improved suspension, a front bumper camera, and enhancements to cabin comfort and noise levels. While the Model Y has mainly received positive customer reviews, anticipation and a wait-and-see mindset for Tesla’s tech-forward customers likely led to a lull in Model Y sales in early 2025. Additionally, Tesla underwent an intensive revamp of its factories in early 2025 to retool them for the new Model Y production. With these short-term barriers in the rearview mirror, the stage is set for an upside surprise on the Model Y front. Also, Tesla’s Cybertruck production is also gaining momentum and becoming more efficient.

4.       China’s Economic Rebound Should Boost Tesla Sales: China is Tesla’s second most important market, comprising ~22% of total revenue. Over the past few years, Tesla sales in China have suffered amid a floundering Chinese economy, plagued by high unemployment. However, following a slew of government stimulus measures and a relaxation of anti-business regulations, China’s economy is firing on all cylinders, registering robust GDP growth of 5% last year.  Meanwhile, following stringent lockdowns and government-driven fear surrounding COVID-19, Chinese households currently enjoy massive excess savings. With a still uncertain housing market, many of these Chinese households are likely to spend on EVs, which are wildly popular in China. If August is any clue for Tesla China’s sales, bulls are in business. Tesla sales jumped to 83,192 units in August, representing a healthy 22.6% rise versus July. The key will be how Tesla fares against tough Chinese competition, such as Nio ((NIO - Free Report) ), XPeng ((XPEV - Free Report) ), and BYD Co. ((BYDDF - Free Report) ).

5.       Lower Interest Rates are a Positive for Tesla: Earlier this month, Fed Chair Jerome Powell delivered a long-awaited interest rate cut. Rate cuts not only stimulate the economy but also lower monthly costs for potential Tesla buyers, incentivizing purchases.

6.       Tariffs Help Tesla Fend Off Foreign Competition: Although Tesla experienced some initial negative impacts from President Trump’s unique tariff policy, overall, they are a net positive for the company. Tariffs increase the costs for foreign-made EVs, making Tesla’s US-manufactured EVs comparatively more attractive.

Betting Markets Suggest Big Tesla Delivery BeatBetting markets are often more accurate than analysts because they benefit from ‘the wisdom of the crowd.’ Also, unlike polls, betting markets mean that betters are investing real money and have ‘skin in the game.’ Popular betting market Kalshi is currently pricing in Q3 Tesla deliveries of 505k, well above Wall Street consensus estimates.

Image Source: Kalshi

Tesla Technical ViewSince its inception, TSLA have increased by a mind-blowing 34k%. That said, long-term charts indicate that TSLA stock performance comes in bunches. From 2014 to 2020, Tesla shares moved sideways as the company transitioned to new products. However, over the next two years, TSLA shares would multiply 17X! Currently, history appears to be repeating itself. Tesla shares have been stagnant since 2022 and are finally breaking out. As the old Wall Street adage goes, “The longer the base, the higher in space.” Should the breakout succeed, the Fibonacci extensions suggest that a reasonable price target for TSLA over the next few months is ~$600.

Image Source: Zacks Investment Research

Can Tesla deliveries be the breakout catalyst?

Why Investors Should Ignore Tesla’s Sky-High P/E RatioFor value-oriented investors, Tesla’s price-to-earnings ratio of 207x makes the stock an automatic avoid.

Image Source: Zacks Investment Research

However, savvy investors understand that valuations require nuance. Investors are willing to place a higher valuation on Tesla because it is arguably the most innovative company in the world. Tesla is likely to be a leader in humanoid robots (which Musk sees as Tesla’s potentially largest future product) and artificial intelligence. In addition, Tesla is slated to release a more affordable version of its wildly popular Model Y SUV in Q4 2025. Finally, Tesla’s energy business is dramatically overlooked by Wall Street analysts. As the US power grid becomes increasingly strained by the insatiable electricity demand from AI data centers, utility companies are investing in Tesla’s Megapack to supplement the grid. Tesla Energy became profitable in mid-2022 and has produced profits in 13 consecutive quarters. Meanwhile, year-over-year energy deployments soared by 113% in 2024 alone. Energy is one of the most predictable trends on Wall Street, and Tesla is set to be a major beneficiary.

Bottom Line

After navigating a challenging period marked by political backlash, slowing EV growth, and market skepticism, Tesla shares are rebounding swiftly. Will this week’s delivery numbers be the catalyst that validates the market’s renewed optimism in Tesla?

Analyst’s Disclosure:I/we have a beneficial long position in the shares of UPWK either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of CRWV either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Posted: September 29, 2025

Key Takeaways
Which Ethereum ETFs were most affected by outflows?
The Fidelity Ethereum Fund (FETH) experienced the largest outflows at over $362 million, followed by BlackRock’s ETHA fund, with more than $200 million exiting.

How did Ethereum’s price perform during this period?
Ethereum traded at $3,990.17, down 0.58% on the day and 10.78% over the past week, reflecting short-term market volatility.

Ethereum [ETH] has been making headlines recently, not just for its price movements, but also due to heightened network activity that has drawn investor attention.

Yet, despite the buzz, spot Ethereum ETFs faced a historic drain last week, recording their largest weekly outflows on record.

Ethereum ETF analysis
Data from Farside Investors shows that for the week ending the 26th of September, these ETFs saw $795.6 million in outflows amid a trading volume surpassing $10 billion.

The ETFs just edged out the previous notable week of the 5th of September, which saw $787.7 million exit the funds.

BlackRock’s industry-leading ETHA fund saw more than $200 million exit, even though the fund still manages over $15.2 billion in assets.

Meanwhile, the Fidelity Ethereum Fund (FETH), the third-largest Ethereum ETF by assets under management, experienced the largest outflows among its peers, with over $362 million pulled during the same period.

Grayscale’s ETHE also reported notable withdrawals, highlighting a broader trend of investor caution in the Ethereum market.

The outflows coincided with Ethereum’s price slipping below the $4,000 mark, trading at $3,990.17, down 0.58% on the day and 10.78% over the past week, according to CoinMarketCap.

The retreat in ETF flows mirrors the wider market sentiment, as investors appeared to pull back amid short-term volatility.

Spot Bitcoin ETFs faced similar pressures
Weekly outflows across available Bitcoin [BTC] ETFs totaled $902.5 million, with Fidelity’s FBTC leading the pack in withdrawals.

Bitcoin itself traded at $109,352.01, reflecting a modest daily decline of 0.02% and a 5.53% drop over the week, according to CoinMarketCap.

What’s more?
This coincided with the SEC has postponing decisions on multiple crypto ETF and staking applications, pushing review deadlines into late October and mid-November.

Major issuers, including BlackRock, Franklin Templeton, Fidelity, 21Shares, and Grayscale, are among those affected.

Yet, despite these delays, market optimism remains, with Ripple [XRP] Futures reaching record highs and new filings emerging, such as VanEck’s proposed Spot Hyperliquid ETF and the first U.S.-based Dogecoin [DOGE] ETF.

Ishika Kumari is a Crypto Analyst and Content Strategist at AMBCrypto, specializing in the analysis of cryptocurrency regulations, market trends, and the socio-political impact of blockchain technology.
Her expertise is grounded in her academic background as a graduate of Political Science from the renowned University of Delhi. This discipline has equipped her with a sophisticated framework for analyzing complex governance models, international regulatory landscapes, and the economic principles that underpin decentralized systems.
At AMBCrypto, Ishika applies this unique analytical lens to her work. She excels at breaking down intricate subjects—from the technicalities of new protocols to the nuances of global crypto legislation—into clear, accessible, and insightful content. Her primary mission is to bridge the gap between the complexity of the digital asset industry and the everyday reader, ensuring that AMBCrypto's audience is not just informed, but truly understands the forces shaping the future of finance.

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

Ripple CEO Brad Garlinghouse’s comments have long emphasized that the value of XRP is rooted in its utility in the financial world rather than speculation or replacing traditional finance as a whole. One of such comments was made in an old interview which has resurfaced to catch the eye of some XRP investors on the social media platform X. Years later, those comments are being revisited as XRP continues to push for adoption in global markets and as investors are counting down to the SEC’s upcoming decision on Spot XRP ETF applications.

Utility Over Hype: Revisiting Garlinghouse’s Message
A recent video which was posted on the social media platform X by popular XRP commentator JackTheRippler ties back into an interview where Garlinghouse noted how trillions in capital could pour into XRP in the coming years. In that conversation, Garlinghouse explained that hype alone cannot sustain the value of any cryptocurrency, insisting instead that true growth comes from solving real-world problems and building a customer base.

These comments were made in a 2017 interview on CNBC’s Squawk Alley, at a time when cryptocurrencies were mostly valued on speculation alone. In the interview, Garlinghouse pointed out that XRP wasn’t just created to trade on exchanges but was meant to serve a real purpose, which is settling liquidity between banks. At the time, he noted that more than $27 trillion was sitting idle in correspondent banking accounts worldwide to facilitate payments between themselves. 

🚨RIPPLE CEO SAYS THAT #XRP SETTLES MONEY IN SECONDS!

TRILLIONS IN CAPITAL COULD POUR INTO XRPL. DRIVEN BY REAL TOKEN, BUILT TO TOKENIZE THE ENTIRE REAL ESTATE SECTOR! DYOR/NFA

💥 GET REAL TOKEN HERE: https://t.co/kYx7u3Ko4Z pic.twitter.com/seidvGLqdy

— JackTheRippler ©️ (@RippleXrpie) September 27, 2025

His vision was that XRP, with its ability to settle transactions in seconds, could free up that capital and make cross-border payments much more efficient. “We use this digital asset called XRP to settle liquidity needs between banks,” he said.

XRPUSD currently trading at $2.78. Chart: TradingView
Even though those words were spoken years ago, they still fit into today’s conversations about XRP. Its adoption potential in the worldwide financial system continues to be the foundation of why many investors believe XRP can stand apart from other cryptocurrencies.

Countdown To US SEC’s Spot XRP ETF Decision
The attention surrounding XRP nowadays is shifting to the regulatory front, with many investors awaiting the outcome of pending Spot XRP ETF applications. After Bitcoin and Ethereum won approval for similar products, many see XRP as the next logical step given its position as the third-largest cryptocurrency.

The US SEC has introduced new listing standards designed to speed up crypto ETF approvals, cutting the review window to 75 days or less. Grayscale’s filing is due for a decision on October 18, followed by 21Shares on October 19, Bitwise on October 20, CoinShares and Canary Capital on October 23, and WisdomTree on October 24.

The eventual launch of a Spot XRP ETF could be the turning point that helps the cryptocurrency take its place alongside Bitcoin and Ethereum in traditional finance.

At the time of writing, XRP was trading at $2.79.

Featured image from Istockphoto, chart from TradingView

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

Sign Up for Our Newsletter!
For updates and exclusive offers enter your email.

Scott Matherson is a leading crypto writer at Bitcoinist, who possesses a sharp analytical mind and a deep understanding of the digital currency landscape. Scott has earned a reputation for delivering thought-provoking and well-researched articles that resonate with both newcomers and seasoned crypto enthusiasts.
Outside of his writing, Scott is passionate about promoting crypto literacy and often works to educate the public on the potential of blockchain.

Binance has once again demonstrated its influence in the crypto ecosystem by rewarding BNB holders through the HODLer Airdrop program, this time supporting Falcon Finance (FF), a rapidly growing stablecoin project. Developed by Andrei Grachev of DWF Labs, Falcon Finance has already achieved a Total Value Locked (TVL) exceeding $100 million within just one month of its beta launch, signaling strong demand from both retail and institutional investors.

Posted: September 29, 2025

Key Takeaways
Why is Ethereum’s price stuck?
Because current buying is being matched by selling, keeping ETH flat even as reserves drop.

Could Ethereum see a short squeeze soon?
With most downside liquidity absorbed and liquidation targets stacked above, a small price move could trigger a sharp short squeeze.

Ethereum [ETH] is up to something big. Over the past few days, sell pressure quietly eased as Exchange Reserves declined while investors moved ETH off trading platforms.

Source: CryptoQuant

With downside liquidity already absorbed, all that’s missing is a spark. And if demand kicks in, even a small catalyst could be enough to send ETH to the moon!

Shorts are running out of room
According to CryptoQuant data, most of the sell pressure has already been absorbed, leaving far fewer liquidation targets below the current price.

What’s interesting is that the bulk of liquidation clusters sat above ETH’s level – a setup that tilts the odds toward an upside squeeze.

Source: CryptoQuant

In simple terms, if ETH makes even a modest move higher, it could force shorts to close positions quickly, triggering a chain reaction of liquidations. That’s how sharp, sudden rallies begin.

Exchange Reserves are falling, but price refuses to budge
ETH steadily flowed out of spot exchanges, which usually shows that investors are buying and moving their coins into self-custody or staking. That’s a bullish sign of trust.

But here’s the twist. Despite these big outflows, the price hasn’t budged much. Why?

Because while buyers are active, sellers are still matching that demand, keeping ETH stuck in place. This pattern often plays out before major rallies.

Once fresh demand kicks in and tips the balance, lower reserves can amplify the upside move. Right now, the groundwork for that rally is being laid.

Momentum is building
Ethereum’s chart showed price holding just above the $4,000 mark after a drop. The RSI was stuck near 38, and the OBV trend has cooled, so there’s weaker volume support.

Source: TradingView

But here’s the catch. Price is sitting right on the 200-day EMA, a level that often acts like a spring for big moves.

If demand sparks here, ETH could rebound sharply as shorts get caught off guard. For now, it’s a wait, but the setup looks fragile.

One push could be enough to flip the momentum very fast.

Some industry voices believe Circle's plan to introduce a transaction reversibility feature could reinforce bitcoin's appeal as a censorship-resistant asset. Institutional Integration vs. Core Crypto Principles Recent reports indicating that Circle, the issuer of the USDC stablecoin, is weighing whether to add a feature which will enable transaction reversal in certain circumstances has sparked controversy.

As investors await the SEC’s decisions on crypto-spot ETFs, BlackRock’s (BLK) activity in the ETF space could be pivotal for XRP.

An iShares XRP Trust could be crucial to the success of an XRP-spot ETF market, given that the ETF issuer has dominated the BTC–spot and ETH-spot ETF markets. Demand for BlackRock’s iShares Bitcoin Trust (IBIT) and iShares Ethereum Trust (ETHA) was pivotal in BTC and ETH reaching record highs in August.

BlackRock’s Head of Digital Assets, Robbie Mitchnick, spoke with Nate Geraci last week about the criteria to list crypto-spot ETFs. While remaining silent on plans for an iShares XRP Trust, he stated:

“We’re looking at things like market cap, liquidity, maturity, but also clarity of investment thesis and overall product and portfolio considerations in terms of how clients’ long-term are going to be able to use products in this space, build the type of portfolio exposures holistically that they want.”

Investor demand could be significant, given that XRP ranks #3 by market cap and considering its real-world utility in global remittances. Notably, investors may also view XRP’s current price level as a strong buying opportunity.

However, it remains uncertain whether BlackRock will list and trade an XRP-spot ETF. Since the SEC approved the Generic Listing Standards for commodity-based shares, ETF issuers may list and trade crypto-spot ETFs that meet the GLS requirements without going through the SEC’s review process.

Behind the scenes, the SEC may, call on issuers to hold back on listing and trading until it has approved the current batch of crypto-spot ETFs. This means BlackRock could list and trade an iShares XRP Trust on October 18 or 19.

Price Action & Technical Analysis: Breakout or Breakdown?
XRP rose 2.17% on Sunday, September 28, following the previous session’s 0.75% gain, closing at $2.8684.

The token tracked the broader market (2.29%), edging closer to the psychological $3 level. Traders are watching the following technical levels:

Support: $2.7 and $2.5.
Resistance: $3, $3.2, $3.335, and the all-time high at $3.66.

In the near term, several key events could dictate price trends:

XRP ETF demand.
Spot ETF headlines: Approval or delays of crypto-spot ETFs and BlackRock’s plans for listing and trading XRP-spot ETFs.
Blue-chip companies’ demand for XRP as a treasury reserve asset.
Regulatory milestones: Ripple’s application for a US-chartered bank license, the Market Structure Bill, and SWIFT-related developments may also influence sentiment.

Catalysts & Scenarios
The balance of ETF flows, regulatory developments, and demand from blue-chip companies could dictate whether XRP breaches support levels or breaks above resistance.

Bearish Scenario

GDLC, BITW, and XRPR ETFs report weak demand or outflows, and BlackRock remains silent on an XRP-spot ETF.
SEC declines XRP-spot ETF applications.
Roadblocks or setbacks to crypto-friendly regulations.
Blue-chip companies downplay appetite for XRP as a treasury reserve asset.
OCC delays or rejects Ripple’s US-chartered bank license.
SWIFT retains market share in global remittances, limiting Ripple’s market access.

These bearish scenarios could push XRP toward $2.7. A drop below $2.7 could bring the $2.5 support level into play.

Bullish Scenario

BITW, GDLC, and XRPR register strong demand.
BlackRock lists and trades an XRP-spot ETF, and the SEC greenlights XRP-spot ETFs.
Blue-chip companies purchase XRP for treasury purposes, and more payment platforms integrate Ripple technology.
Ripple secures a US-chartered bank license, and the Market Structure Bill passes the Senate.
SWIFT loses market share of global remittances to Ripple.

These scenarios could drive XRP toward $3. A break above $3 could pave the way to $3.2.

Bitcoin price action has stirred fresh debate after attempting a bounce near $109,000, sparking speculation of a push back toward $110,000. However, this recovery effort looks fragile and lacks the conviction needed for a true reversal. Technical signals continue to highlight weakness rather than strength.

Recently, Bitcoin slipped under its 50-day EMA at $113,700 and the 100-day EMA at $112,200, both now acting as strong resistance levels. The cryptocurrency is currently hovering just above the 200-day EMA around $106,200, which historically serves as a critical long-term support line for bulls. Yet, this latest bounce did not originate from the 200 EMA but appears instead to be a shallow attempt to reclaim lost ground after several days of heavy selling.

What makes this rebound appear unreliable is the lack of strong buying volume. Unlike previous recoveries from oversold conditions or robust support zones, this move lacks momentum, suggesting buyers are hesitant to step in with force. Trading activity remains muted, reinforcing concerns that any gains could be unwound quickly.

The Relative Strength Index (RSI) is sitting near 38, signaling weakness but not quite oversold levels. This leaves room for further downside if bearish sentiment re-emerges. To confirm a sustainable comeback, Bitcoin must reclaim the $112,000–$114,000 range, where broken EMAs now block the path upward. Only a decisive break above that zone would indicate the possibility of a stronger bullish reversal.

Until then, Bitcoin remains at risk of retesting $106,000 and the 200 EMA, the last significant defense for bulls. Any short-term rallies without meaningful volume are vulnerable to quick reversals. The market’s true test lies ahead: either regain critical resistance levels and rebuild confidence, or face the possibility of another leg lower.

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>

The company has multiple trends working in its favor.

Chewy (CHWY 4.52%) is the type of stock the market doesn't pay nearly enough attention to because it's in a category that doesn't grab headlines. The company isn't chasing some cutting-edge technology like artificial intelligence (AI) or quantum computing, it's selling pet food and supplies. However, it's built an attractive retail model with significant recurring revenue, and that type of business is very valuable.

Image source: Getty Images.

An attractive Autoship business
The beauty of Chewy is in its business model. The company has close to 21 million active customers, and most importantly, more than 80% of its sales come from customers that have used Autoship in the past year. This program allows Chewy's customers to set up recurring deliveries for items like dog food and cat litter. Autoship sales give Chewy a predictable revenue stream that is much less tied to economic cycles. Add in the fact that about 85% of its sales come from non-discretionary product categories, and you have an e-commerce business that looks a lot closer to Walmart or Tractor Supply Company in terms of resiliency.

Notably, though, Chewy is growing its revenue at a faster pace than these brick-and-mortar retailers, and it's expanding its gross margin by layering in several higher-margin revenue streams. The company has taken a page out of Amazon's playbook by turning to sponsored ads to help drive growth. This business carries gross margins of around 70%, which is more than double the 30% overall gross margin the company posted in Q2.

The company also continues to grow its health and pharmacy business, which can carry gross margins that are as much as 10 percentage points higher than its retail business. While Hims & Hers Health gets a lot of press about its drug compounding business, Chewy is actually one of only two companies in the U.S. that does pet medication compounding at scale, which carries even higher gross margins. With less than a quarter of its customers using its pharmacy services, this business has a long runway of growth.

The company is also leaning into private-label brands, which carry margins about 700 basis points higher than national brands. The company has seen solid momentum in this area and just recently launched a healthy, fresh dog food line called Get Real that competes with Freshpet and others. It has also followed in the steps of Amazon and Walmart by adding a paid membership program with perks that could not only help expand margins but also deepen customer relationships.

Time to buy the stock
Chewy stock pulled back earlier this month after the company reported its fiscal Q2 results due to rising operating expenses. However, results were still strong overall. Revenue jumped 8.6%, led by a 14.9% increase in Autoship customer sales (which includes all sales from recent Autoship customers, regardless of whether those sales were made through the subscription program). Meanwhile, it added 150,000 new customers in the quarter and saw its net sales per active customer climb 4.6% to $591.

The longer-term outlook for the company is also attractive. Pet ownership has been climbing for decades, and people continue to treat pets more like family, which is increasing their spending. Chewy has positioned itself not only as the go-to online retailer for pet food and supplies but also increasingly for pet health, where spending is rising even faster.

Lastly, the stock is attractively priced with a forward price-to-earnings (P/E) ratio of around 25 based on fiscal 2026 analyst estimates. That's a nice discount compared to other recession-resistant retailers such as Costco and Walmart, and similar to Tractor Supply Company.

Data by YCharts.

What investors are missing is that Chewy has already built a repeat customer base most e-commerce companies would envy, and it's now targeting new opportunities that should lead to earnings growth outpacing sales growth for years. The recent sell-off on a temporary uptick in expenses does not change that.

Chewy deserves a lot more attention than it is getting. Investors who are willing to buy this top e-commerce stock while it is still overlooked could enjoy market-beating returns long term.

Geoffrey Seiler has positions in Chewy. The Motley Fool has positions in and recommends Amazon, Chewy, Costco Wholesale, Freshpet, Hims & Hers Health, Tractor Supply, and Walmart. The Motley Fool recommends the following options: short October 2025 $60 calls on Tractor Supply. The Motley Fool has a disclosure policy.

Numerous trends working in the company's favor make this stock a smart dividend growth investment.

Had an investor bought $1,000 worth of stock in Badger Meter (BMI 0.92%) and its water management solutions in 1990 and held until today while reinvesting dividends, it would be worth $288,000.

While the water innovation leader will be hard-pressed to repeat those results over the next 35 years, Badger Meter stock is still only at a $5 billion market cap despite this incredible run.

Simply put, Badger Meter's growth story has plenty of room to run, and it looks like an excellent dividend growth stock to consider if you have $1,000 available to invest right now -- especially with its shares down 32% from their highs.

Badger Meter's top-tier sales and dividend growth
Though the company's flow measurement and advanced metering infrastructure products don't typically elicit thoughts of massive growth potential, Badger Meter has proved otherwise.

Its sales and free cash flow (FCF) have grown by 15% and 16% over the last five years, while management has increased the dividend by 14% at the same time.

With most water and sewer utilities in the United States still largely mechanical and outdated, Badger Meter's end-to-end BlueEdge solution aims to bring these utilities into the modern era.

Image source: Getty Images.

Whether it is the company's continuous monitoring, always-on connectivity, or its full suite of software solutions, the products will only become more important over time as regulations tighten and quality standards increase.

In addition to having the support of this decades-long megatrend, Badger Meter has an excellent track record as a serial acquirer. It has scooped up 14 companies since 2010 and is continuously reinforcing its leadership position.

Adding numerous software and technology solutions via these acquisitions, the company's FCF margin has jumped from 6% in 2015 to 18% today as its software-as-a-service (SaaS) sales balloon.

This burgeoning FCF generation is what makes Badger Meter such a promising dividend growth investment for investors.

While its 0.8% dividend yield may not be jaw-dropping, it only uses 25% of the company's FCF to make dividend payments to shareholders. This figure shows there is a lot of room for further dividend growth, especially as Badger Meter's FCF margin continues to trend higher.

Josh Kohn-Lindquist has positions in Badger Meter. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

AGNC Investment has a massive 14%+ yield, but buying for the yield alone could set you up for disappointment.

AGNC Investment (AGNC 0.87%) is likely to show up on a lot of dividend screens thanks to its massive 14%+ dividend yield. A yield that high can often be a sign of a troubled business, but not in the case of this mortgage real estate investment trust (mREIT). In fact, the mREIT does a fairly good job at achieving its main goal. The problem is that the goal AGNC is working toward may not be the goal you have in mind. Here's what you need to know.

What does AGNC Investment do?
AGNC Investment operates in a niche of the real estate investment trust sector. Property-owning REITs buy physical assets and lease them out to tenants, which is what you would do if you owned a rental property. It's a fairly easy business model to wrap your head around. AGNC doesn't do that; it buys mortgages that have been pooled into bond-like securities. That's not an easy business model to understand.

Image source: Getty Images.

In many ways, AGNC Investment is more like a mutual fund than a property-owning REIT. In fact, AGNC even provides investors with a metric it calls tangible net book value per share each quarter. This figure is, basically, the value of the mortgage security portfolio on a per-share basis. It is similar to the net asset value (NAV) that a mutual fund reports daily.

This is more important than it may seem, because AGNC Investment's objective isn't to generate a reliable income stream. The goal is "favorable long-term stockholder returns with a substantial yield component." Essentially, the goal is total return, which requires that dividends get reinvested. If you are trying to use the dividends you collect from AGNC to pay for living expenses, you are likely to be let down by this investment.

How has AGNC Investment performed?
Starting with AGNC's actual objective, the mortgage REIT has done a pretty good job. As the chart below highlights, reinvesting the dividends you receive from AGNC Investment would leave you with a total return that is fairly close to that of the S&P 500 index (^GSPC 0.59%) since the mREIT went public. And since the two graphs don't match up perfectly, AGNC looks like it could add some important diversification to your portfolio.

AGNC Total Return Level data by YCharts

The problem arises when you look past total return to examine the stock price and dividend history. When you do, you see that AGNC Investment's dividend is highly volatile. In fact, it has been heading lower for around a decade. The stock price has tracked along with the dividend. The outcome is that investors that spent the dividend would have ended up with less capital and less income. That's not what most dividend investors are looking for.

AGNC data by YCharts

There's a caveat here, though. If you add up all of the dividends that have been paid by AGNC over its history and compare that to the drop in the price of the stock, you'll find some interesting figures. Basically, more dividends have been paid out than value has been lost due to stock price declines. So, from a big-picture perspective, dividend investors have done OK. And still, less income and less capital is not what most dividend investors are likely to be looking for.

AGNC Investment isn't bad; it is just a specialized investment
AGNC Investment has largely achieved its total return goal. The problem is that most dividend investors don't have the same goal. Most dividend investors want a dividend and stock price that are stable or growing over time. If you get too caught up in the huge yield AGNC is offering, you might end up owning something that doesn't align well with your investment goals.

Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

September 28, 2025 19:30 ET

 | Source:

Biogen Inc.

TOKYO and CAMBRIDGE, Mass., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (brand name in China: “乐意保®”, generic name: lecanemab) has been approved for once every four weeks intravenous (IV) maintenance dosing by the National Medical Products Administration (NMPA) in China.

In January 2024, LEQEMBI was approved for the treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD) in China. After 18 months of a dosing regimen of 10 mg/kg once every two weeks during initiation phase, a transition to the maintenance dosing regimen of 10 mg/kg once every four weeks may be considered or the regimen of 10 mg/kg once every two weeks may be continued.

AD is a progressive, relentless disease characterized by formation of protein deposits known as plaques made of amyloid-beta aggregates and neurofibrillary tangles made of tau protein in the brains of people living with AD. It is caused by a continuous underlying neurotoxic process that begins before amyloid plaque accumulation and continues after plaque removal.1,2,3,4 The data show that Aβ protofibrils* and tau tangles play roles in the neurodegeneration process,2,3 and LEQEMBI is the only approved therapy that fights AD in two ways — targeting both amyloid plaque and protofibrils, which can impact tau downstream.

Eisai estimates that, as of 2024, there were 17 million patients with MCI or mild dementia due to AD in China in 2024, which is expected to increase with the aging of the population.

Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. In China, Eisai distributes the product and conducts information provision activities through specialized Medical Representatives.

*Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.1 Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.4 MEDIA CONTACTS Eisai Co., Ltd.
Public Relations Department
+81 (0)3-3817-5120Eisai Europe, Ltd.
(UK, Europe, Australia, New Zealand and Russia)
EMEA Communications Department
+44 (0) 7739 600678
[email protected]

Eisai Inc. (U.S.)
Libby Holman
+ 1-201-753-1945
[email protected]

Biogen Inc.
Madeleine Shin
+ 1-781-464-3260
[email protected] CONTACTS Eisai Co., Ltd.
Investor Relations Department
+81 (0) 3-3817-5122Biogen Inc.
Tim Power
+ 1-781-464-2442
[email protected] Notes to Editors
1.About LEQEMBI (generic name: lecanemab, Chinese brand name: 乐意保)
Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.Lecanemab has been approved in 50 countries and is under regulatory review in 10 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks was approved in China, the U.S. and others, and applications have been filed in 5 countries and regions.LEQEMBI's approvals in these countries were based on Phase 3 data from Eisai's, global Clarity AD clinical trial, in which it met its primary endpoint and all key secondary endpoints with statistically significant results. The primary endpoint was the global cognitive and functional scale, Clinical Dementia Rating Sum of Boxes (CDR-SB).1,5 The U.S. FDA approved Eisai’s Biologics License Application (BLA) for subcutaneous maintenance dosing with LEQEMBI IQLIK in August 2025. In September 2025, the rolling sBLA application to the U.S. FDA for the subcutaneous initiation dosing with LEQEMBI IQLIK was also initiated.

Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.

2.About the Collaboration between Eisai and Biogen for AD
Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.

3.About the Collaboration between Eisai and BioArctic for AD
Since 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.4.About Eisai Co., Ltd.
Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai. Co., Ltd.), us.eisai.com (for U.S. headquarters: Eisai, Inc.) or www.eisai.eu (for Europe, Middle East, Africa, Russia, Australia and New Zealand headquarters: Eisai Europe Ltd.), and connect with us on X (global and U.S), LinkedIn (for global, U.S. and EMEA) and Facebook (global).

5.About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth. The company routinely posts information that may be important to investors on its website at www.biogen.com. Follow Biogen on social media – Facebook, LinkedIn, X, YouTube. Biogen Safe Harbor
This news release contains forward-looking statements, including about the potential clinical effects of lecanemab; the potential benefits, safety and efficacy of lecanemab (marketed as 乐意保 in China); potential regulatory discussions, submissions and approvals and the timing thereof; the causes and treatment of Alzheimer's disease; the anticipated benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and uncertainties associated with drug development and commercialization. These statements may be identified by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "may," "plan," "possible," "potential," "will," "would" and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical studies may not be indicative of full results or results from later stage or larger scale clinical studies and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements.These forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to differ materially from those stated or implied in this document, including, among others, uncertainty of our long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans, prospects and timing of actions relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product competition in the biopharmaceutical and healthcare industry, as well as any other markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways; our ability to effectively implement our corporate strategy; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; the drivers for growing our business, including our dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; risks related to commercialization of biosimilars, which is subject to such risks related to our reliance on third-parties, intellectual property, competitive and market challenges and regulatory compliance; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; and the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in reports we have filed with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov.These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our subsequent reports on Form 10-Q. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.

   References

Eisai presents full results of lecanemab Phase 3 confirmatory Clarity AD study for early Alzheimer's disease at Clinical Trials on Alzheimer's Disease (CTAD) conference. Available at: https://www.eisai.co.jp/news/2022/news202285.htmlHampel H, Hardy J, Blennow K, et al. The amyloid pathway in Alzheimer's disease. Mol Psychiatry. 2021;26(10):5481-5503.Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi:10.1038/s41467-021-23507-zOno K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.van Dyck. C, et al. Lecanemab in Early Alzheimer’s Disease. The New England Journal of Medicine. DOI: 10.1056/NEJMoa2212948. https://www.nejm.org/doi/full/10.1056/NEJMoa2212948

Targeting Phase 1 commissioning by the end of 2026 HIGHLIGHTS Existing fully permitted Central Gawler Mill adjacent to brownfield Challenger mines Challenger JORC (2012) Mineral Resources Estimate now 313koz Au (10.6Mt @ 0.92 g/t), including 194koz Au (1.87Mt @ 3.23 g/t) in existing open pit and underground mines, where: Challenger Main Open Pit: 70,000oz Au (0.65Mt @ 3.36 g/t Au); Challenger West Open pit: 11,600oz Au (0.03Mt @ 10.7 g/t Au); Challenger Underground (above 215mRL): 89,400oz Au (0.98Mt @ 2.84 g/t Au); and Challenger Deeps (below 90mRL): 23,000oz Au (0.21Mt @ 3.50 g/t Au). Historical tailings storage facility with coarse, higher-grade tailings up to 0.6 - 1.0 g/t Au Evaluating de-risked, two phase transition to operations with initial tailings reprocessing ('Phase 1') followed by the introduction of high-grade (~3 g/t) fresh ore ('Phase 2') Targeting Phase 1 commissioning by end of 2026; credit finance conversations underway ADELAIDE, AU / ACCESS Newswire / September 28, 2025 / Barton Gold Holdings Limited (ASX:BGD)(OTCQB:BGDFF)(FRA:BGD3) (Barton or Company) is pleased to announced that a Definitive Feasibility Study (DFS) has started, targeting 'Stage 1' production utilising the fully permitted Central Gawler Mill (CGM) located at Barton's South Australian Challenger Gold Project (Challenger).

You don't need super-intelligence to figure out why these two dividend stocks are smart long-term investments.

"The true investor...will do better if he forgets about the stock market and pays attention to his dividend returns." -- Benjamin Graham

Many investors follow closely the ups and downs of the stock market, waiting for share price gains. Many investors also overlook another strong source of returns: the dividends many companies dish out to shareholders. If you're browsing for ideas, here are two rock-solid companies with economic moats and a dividend to pay you while you sleep!

Flying high
When it comes to investments, a pretty good place to start is the U.S. Department of Defense, the largest military budget on planet Earth. It's what has made Lockheed Martin (LMT 0.66%) a bellwether of the defense contracting industry after deriving roughly 75% of its $71 billion in sales last year servicing contracts from the DoD.

The great news for long-term investors is that it's a stable source of revenue, as its F-35 contract is the largest defense procurement program ever awarded, and goes through the 2060s. You also won't be shocked to hear that so-called rivals, such as China, Russia, and even hot spots like Iran and North Korea, aren't going away anytime soon. As such, the U.S. defense spending is likely to increase under the Pentagon's focus to modernize the military's ability -- and that's good news for Lockheed Martin investors.

F-35A Lightning II Image source: Lockheed Martin.

Further, Lockheed sent a memo to investors recently, reminding everyone that it also makes pretty impressive drones, too. Not even a week ago, Lockheed unveiled Vectis, a "lethal collaborative combat aircraft to advance unparalleled air dominance for American and allied militaries."

Vectis is a drone designed to work with fighter jets and intended to be a fast-developed, stealthy, and affordable jet. It's a good sign for long-term investors who were concerned Lockheed's business would suffer if drones began replacing manned platforms, such as its lucrative F-35, over the coming decades.

Lockheed trades at a price-to-earnings ratio of 27 times, and also offers investors a healthy dividend yield of 2.7%, while investors enjoy the stability of its long-term lucrative F-35 contract as well as its expanding drone business.

Big time brewer
Ambev (ABEV 0.22%) is the largest brewer in Latin America and the Caribbean, and is Anheuser-Busch InBev's subsidiary in the region; it produces, distributes, and sells beer as well as PepsiCo products in Brazil and other Latin American countries and was formed in 1999 through a merger of Brazil's two largest beverage companies, Brahma and Antarctica.

With that history lesson aside, the company has proven it can dominate markets. In fact, Ambev has monopolistic positions across regions that include roughly 60% beer market share in Brazil, 65% in Argentina, El Salvador, and Uruguay, and over 70% in Bolivia, according to Morningstar.com.

Here's the upside for investors: Per capita beer consumption across most Latin American countries is lower than typically found in developed countries, which should pave the way for valuable volume growth for Ambev. The company also has a trick up its sleeve because there's been a noticeable trend of consumers opting for foreign beers over domestic ones, which is an opportunity for Ambev to leverage Anheuser-Busch InBev's wide premium portfolio that includes Budweiser, Corona, and Michelob Ultra.

It's tough for regional competition to match the scale of Ambev, and the company should be able to maintain its market share through economic cycles while still dishing out its high-yield dividend of 7.6%.

Time to buy?
Both of these stocks offer investors a healthy dividend, long-term potential, and competitive advantages. The product complexity in Lockheed Martin's defense business helps keep new entrants on the sidelines, while its lengthy F-35 contract gives financial stability and transparency. Ambev has a strong scale advantage over regional peers and plenty of room for growth if developing countries increase their beer consumption and continue reaching for premium import brands. Both stocks can be cornerstones in many portfolios looking for some dividend income.

Daniel Miller has no position in any of the stocks mentioned. The Motley Fool recommends Lockheed Martin. The Motley Fool has a disclosure policy.

A flame rises from a chimney of an oil field in Iraq's Kurdistan region, August 16, 2014. REUTERS/Azad Lashkari/File Photo Purchase Licensing Rights, opens new tab

SummaryKurdistan crude flows to Turkey resumes after 2-1/2 year haltOPEC+ plans another oil output hike in November, sources sayRussia pounds Ukraine in mass drone and missile attackSINGAPORE, Sept 29 (Reuters) - Oil prices slipped nearly 1% on Monday after Iraq's Kurdistan region resumed crude oil exports via Turkey over the weekend and as OPEC+ plans another oil output hike in November, adding to global supplies.

Brent crude futures fell 63 cents, or 0.90%, to $69.50 a barrel by 0023 GMT after settling at the highest since July 31 on Friday. U.S. West Texas Intermediate crude was trading at $65.07 a barrel, down 65 cents, or 0.99%, giving back most of Friday's gains.

Sign up here.

"Ongoing fears of production increase are limiting gains, but a tight near term outlook has crude prices in a vice as the trading week begins," said Michael McCarthy, CEO of investor platform Moomoo Australia and New Zealand.

Crude oil flowed on Saturday through a pipeline from the semi-autonomous Kurdistan region in northern Iraq to Turkey for the first time in 2-1/2 years, after an interim deal broke a deadlock, Iraq's oil ministry said.

The agreement between Iraq's federal government, the Kurdistan regional government (KRG) and foreign oil producers operating in the region will allow 180,000 to 190,000 barrels per day of crude to flow to Turkey's Ceyhan port, Iraq's oil minister told Kurdish broadcaster Rudaw on Friday.

The U.S. had pushed for a restart, which is expected to eventually bring up to 230,000 bpd of crude back to international markets at a time when OPEC+ is boosting output to gain market share.

The Organization of the Petroleum Exporting Countries and their allies, or OPEC+, will likely approve another crude production hike of at least 137,000 bpd at its meeting on Sunday, as rising oil prices encourage the group to try to further regain market share, three sources familiar with the talks said.

However, OPEC+ has been pumping almost 500,000 bpd less than its targets, defying market expectations of a supply glut.

Brent and WTI rose more than 4% last week, their biggest weekly gains since June, as Ukraine's drone attacks on Russia's energy infrastructure cut the country's fuel exports.

Russia pounded Kyiv and other parts of Ukraine early on Sunday in one of the most sustained attacks on the capital since the full-scale war began.

Reporting by Florence Tan; Editing by Leslie Adler and Jamie Freed

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

1 hour ago

Bitcoin will perform like Nvidia and record several major corrections on its path to new all-time highs, analyst Jordi Visser said.

2920

The path to new Bitcoin (BTC) all-time highs will continue to feature major corrections of 20% or more, including possible corrections during Q4, despite it typically being a good quarter for crypto asset prices, according to market analyst Jordi Visser.

Visser said Bitcoin is part of the AI trade and compared BTC to Nvidia, a high-performance computer chip manufacturer that has become the world’s most valuable publicly traded company and the first public company to hit a $4 trillion valuation. Visser said:

“I just want to remind people that Nvidia is up over 1,000% since ChatGPT’s launch. During that time period, which is less than three years, you've had five corrections of 20% or more in Nvidia before it went back up to all-time highs. Bitcoin's going to do the same thing.”Nvidia’s stock performance shown as price candles, while Bitcoin is displayed as a magenta line. Both have experienced sharp corrections despite the bull market. Source: TradingviewAs artificial intelligence takes over more sectors of the economy and replaces human labor, it will erode traditional companies and make stocks obsolete, driving investors to BTC, which will be the best store of value in the digital age, Visser predicted.

The price of Bitcoin is one of the most debated and analyzed topics in crypto, as market analysts attempt to forecast the digital currency’s price trajectory amid a time of rapid technological innovation, market disruption, and fiat currency debasement.

Analysts grapple with slow-moving Bitcoin performanceMarket analysts are watching gold and stocks hit new all-time highs while Bitcoin’s price remains near the $110,000 level, down by about 11% from its all-time high of over $123,000.

Investors are divided on whether new highs are possible in Q4, catapulting BTC to about $140,000, or if the recent drawdown represents the start of a prolonged bear market that could take BTC’s price down to $60,000.

Regulatory hurdles and the lack of progress on a Bitcoin strategic reserve in the United States that grows through periodic market purchases have dampened expectations for some analysts.

Previously, some analysts forecast that US government purchases of BTC for a national Bitcoin reserve would be a major price catalyst for the digital asset in 2025.

Magazine: Recursive inscriptions: Bitcoin ‘supercomputer’ and BTC DeFi coming soon

The digital asset treasury (DAT) market has reached a turning point after Strive (ASST) announced an all-stock deal to acquire Semler Scientific (SMLR), marking the first-ever merger of two publicly traded bitcoin treasuries. Industry insiders say this move could trigger a wave of consolidation across the sector as companies look for scale, efficiency, and stronger access to capital markets.

The deal is designed to unify bitcoin holdings, boost bitcoin per share, and simplify governance. Once completed, the merged entity will hold nearly 11,000 BTC, supported by Strive’s simultaneous $675 million purchase of 5,885 coins. For Semler, whose stock traded below the value of its bitcoin, the acquisition highlights how non-core businesses may be overshadowed by treasury strategies. Strive CEO Matt Cole emphasized that the transaction is “accretive in bitcoin per share,” aligning with the company’s growth goals and improving capital market access.

Industry experts suggest three key paths forward for DATs. First, further DAT-to-DAT mergers, similar to the Strive-Semler deal, will consolidate balance sheets and maximize bitcoin per share. Second, acquiring cash-flowing businesses could help treasuries offset dilution and fund ongoing BTC accumulation. Japan’s Metaplanet, the nation’s largest bitcoin holder, has already outlined plans to acquire profitable companies while exploring financing tools such as perpetual preferred stock, a strategy pioneered by MicroStrategy (MSTR).

Finally, industry players are expected to favor direct mergers with established businesses instead of using SPACs, which often bring dilution, redemptions, and regulatory complications. Aligning with legitimate operators provides more stability and investor confidence.

The growing maturity of DATs is also reflected in partnerships like FRNT Financial’s recent consulting deal with a digital asset treasury holding $100 million in bitcoin. As consolidation and diversification accelerate, DATs are set to evolve beyond simple BTC holding companies into more complex, growth-driven enterprises, shaping the next era of digital asset treasury strategies.

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>